A clinical study to evaluate efficacy of Dalzbone capsules in fracture healing of long bone fracture of leg

Non randomized, open label clinical study to evaluate efficacy of Dalzbone capsules in fracture healing of long bone fracture of leg

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/06/005850

Enrollment

Registered

2015-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- long bone fracture of leg

Interventions

Intervention1: Dalzbone: each capsule of Dalzbone contains standardized extract of leaves of Dalbergia sissoo (shisham)- 300mg Dosage: two capsule 2 times a day Route of administration: Oral Duration

Eligibility

Inclusion criteria

Inclusion criteria: -Radiologically diagnosed traumatic, simple as well as closed long bone fracture of Arms and leg. -Fractures with internal fixation. -Willing to give inform consent. -0-5 days from the incident of fracture

Exclusion criteria

Exclusion criteria: -Pathological fracture. -Fracture patients with diabetes. -Pregnant and breast feeding women. -Patients with end organ failure. -History of allergy to herbal medicines.

Design outcomes

Primary

Measure	Time frame
Fracture union confirmed by radiological assessmentTimepoint: at baseline after four week after six week and after eight week	—

Secondary

Measure	Time frame
Restoration of functional motility confirmed by clinical assessmentTimepoint: at baseline after four week after six week and after eight week	—

Countries

India

Contacts

Public ContactDrAmol Deshmukh

Pharmanza Herbal Pvt. Ltd.

rd@pharmanzaherbals.com9898652936

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026